Combination Hypertension Agents Market
Number of pages: 100 | Report Format: PDF | Published date: June 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
4.20% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global combination hypertension agents market is expected to register a revenue CAGR of 4.20% in the forecast years from 2023 to 2031
Combination Hypertension Agents Market Fundamentals
Combination hypertension agents, also known as combination antihypertensive therapy, are medications used to treat high blood pressure (hypertension) by combining two or more different classes of antihypertensive drugs. Hypertension is a common medical condition that affects a significant portion of the population. If left untreated, it can lead to various chronic conditions such as cardiovascular and kidney diseases.
Combination therapy is often employed in managing hypertension when single-drug therapy fails to achieve optimal control over blood pressure. By using multiple medications with complementary mechanisms of action, combination agents can enhance the overall efficacy of treatment, lower blood pressure more effectively, and potentially reduce the risk of cardiovascular events.
Market players have been increasing the introduction of combination drugs for hypertension in the market. Pharmaceutical companies recognize the benefits of combination therapy in achieving optimal blood pressure control and reducing the risk of cardiovascular events. Moreover, combination drugs streamline the treatment regimen by combining multiple antihypertensive medications into a single pill or fixed-dose combination. This approach reduces the number of pills patients must take daily, making it more convenient and improving medication adherence.
Combination Hypertension Agents Market Dynamics
Increasing incidences of hypertension are the major factor driving the global combination hypertension agents market. According to a 2023 report by the World Health Organization, approximately 1.28 billion adults between the ages of 30 and 79 have high blood pressure globally. Most of these individuals (two-thirds) reside in low- and middle-income countries. This trend is expected to increase in the forecast years due to rising incidences of obesity, genetic factors, and high salt intake. In 2020, the National Center for Biotechnology Information reported that 65 to 78 percent of primary hypertension cases are caused by excess fat tissue. This is due to the intricate changes that occur in the body, which can lead to the development or exacerbation of hypertension.
Furthermore, increasing research and development on treating hypertension through combination therapy is another key factor supporting the global combination hypertension agents market. According to a recent study, a combination antihypertensive product that includes quarter doses of four different drugs may successfully achieve target blood pressures in patients with just one step. According to the QUARTET-USA study, patients with mild to moderate hypertension experienced a decrease in blood pressure of nearly 5 mm Hg over a 12-week follow-up period when treated with multiple antihypertensive agents, compared to those who received only one agent at a standard dose. Many pharmaceutical companies are collaborating to introduce new combination drugs in the market. In January 2023, Ahngook Pharmaceutical and CMG Pharmaceutical signed a contract to jointly promote Amortan-R Tab, a three-drug combination treatment for hypertension and dyslipidemia.
Clinical guidelines and recommendations from professional organizations, such as the American Heart Association (AHA) and the European Society of Cardiology (ESC), influence treatment practices in hypertension management. These guidelines often recommend combination therapy in specific patient populations, driving the adoption and use of combination hypertension agents. For example, the American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend combination therapy for patients with stage 2 hypertension or those with comorbid conditions such as diabetes or chronic kidney disease. This has led to increased use of fixed-dose combination drugs that combine multiple blood pressure medications into one pill.
Restraining factors in the combination hypertension agents market include the high cost of these drugs, limited accessibility in low-income regions such as Africa, and the potential for adverse side effects.
Market Ecosystem
The global combination hypertension agents market is analyzed from three perspectives: by drug class, distribution channel, and region.
Combination Hypertension Agents Market by Drug Class
Based on drug class, the global combination hypertension agents market is segmented into β blockers and diuretics, angiotensin-converting-enzyme inhibitors and diuretics, angiotensin-converting-enzyme inhibitors and calcium channel blockers, angiotensin receptor blockers and calcium channel blockers, angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers, and others.
The angiotensin receptor blockers and calcium channel blockers segment accounted for the majority of the global combination hypertension agents market revenue share in 2022. This trend is expected to continue over the forecast period due to these drugs' high efficacy and safety profiles. Angiotensin receptor blockers work by blocking the actions of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. Calcium channel blockers, on the other hand, prevent calcium from entering the muscle cells of the heart and blood vessels, resulting in relaxation and widening of the blood vessels. This combination therapy is often prescribed to patients with hypertension who do not respond well to monotherapy with either drug. Moreover, many market players are launching drugs with this combination. For instance, Novartis launched a combination drug called Exforge, which combines an angiotensin receptor blocker and a calcium channel blocker and has been shown to reduce blood pressure in patients with hypertension effectively.
Combination Hypertension Agents Market by Distribution Channel
Based on the distribution channel, the global combination hypertension agents market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the majority of the global combination hypertension agents market share. This is primarily due to the increasing patient pool for hypertension. Additionally, the availability of a wide range of combination hypertension agents in hospital pharmacies is driving the growth of this segment. The convenience of purchasing all necessary medications in one place also appeals to patients and healthcare providers. Furthermore, hospital pharmacies often have specialized pharmacists who can provide expert advice and guidance on medication management for patients with hypertension. As a result, the hospital pharmacies segment is expected to maintain its dominant position in the global combination hypertension agents market in the coming years.
Combination Hypertension Agents Market by Region
Based on the region, the combination hypertension agents market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
North America accounted for the majority of the global combination hypertension agents market in 2022. The high prevalence of hypertension in the region and the increasing geriatric population are expected to drive market growth in the coming years. For instance, in the United States, the combination hypertension agents market is expected to grow due to the rising cases of hypertension among adults and increasing awareness about the importance of early diagnosis and treatment. According to the Centers for Disease Control and Prevention, hypertension was responsible for 691,095 deaths in the United States in 2021, either as the main cause or as a contributing factor. Additionally, favorable government initiatives to control hypertension further fuel market growth. The availability of advanced healthcare infrastructure and favorable reimbursement policies are further contributing to the market growth in North America. The United States is the largest contributor to the regional market, owing to the presence of major market players and high healthcare expenditure. However, the market in Canada is also expected to witness significant growth due to the increasing adoption of combination hypertension agents and rising awareness about the benefits of early diagnosis and treatment of hypertension.
The Asia Pacific combination hypertension agents market is projected to grow significantly in the forecast years. This growth can be attributed to the increasing prevalence of hypertension in the region, coupled with rising healthcare expenditure and government initiatives to promote early diagnosis and treatment of the condition. Additionally, the availability of a wide range of combination hypertension agents in the market is expected to drive further growth. These agents offer the advantage of improved efficacy and reduced side effects compared to traditional monotherapy, making them an attractive option for patients and healthcare providers alike.
Hypertension Agents Market Competitive Landscape
Some of the prominent companies having the largest revenue share in the global combination hypertension agents market are,
Combination hypertension agents, also known as combination antihypertensive therapy, are medications used to treat high blood pressure (hypertension) by combining two or more different classes of antihypertensive drugs.
The global combination hypertension agents market has been growing steadily over the years due to factors such as an increase in the prevalence of hypertension, a rise in awareness about the benefits of combination therapy, and the development of new and improved combination therapies.
The global combination hypertension agents market is expected to register a revenue CAGR of 4.20% in the forecast period from 2023 to 2031.
North America region led the combination hypertension agents market in 2022.
Some of the prominent market players in the global combination hypertension agents market include Novartis AG, Merck & Co., Inc., Pfizer, and Teva Pharmaceuticals Industries Ltd.
*Insights on financial performance are subject to the availability of information in the public domain